PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma
PBRM1, encoding for a subunit of the SWI/SNF complex, is the second most frequently mutated gene in clear cell renal cell carcinoma (ccRCC). Here, the authors show that PBRM1 loss reduces IFNγ-mediated signalling resulting in a less immunogenic tumor microenvironment and that PBRM1 mutations correla...
| Main Authors: | , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2020-05-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-15959-6 |
| _version_ | 1828972899498721280 |
|---|---|
| author | Xian-De Liu Wen Kong Christine B. Peterson Daniel J. McGrail Anh Hoang Xuesong Zhang Truong Lam Patrick G. Pilie Haifeng Zhu Kathryn E. Beckermann Scott M. Haake Sevinj Isgandrova Margarita Martinez-Moczygemba Nidhi Sahni Nizar M. Tannir Shiaw-Yih Lin W. Kimryn Rathmell Eric Jonasch |
| author_facet | Xian-De Liu Wen Kong Christine B. Peterson Daniel J. McGrail Anh Hoang Xuesong Zhang Truong Lam Patrick G. Pilie Haifeng Zhu Kathryn E. Beckermann Scott M. Haake Sevinj Isgandrova Margarita Martinez-Moczygemba Nidhi Sahni Nizar M. Tannir Shiaw-Yih Lin W. Kimryn Rathmell Eric Jonasch |
| author_sort | Xian-De Liu |
| collection | DOAJ |
| description | PBRM1, encoding for a subunit of the SWI/SNF complex, is the second most frequently mutated gene in clear cell renal cell carcinoma (ccRCC). Here, the authors show that PBRM1 loss reduces IFNγ-mediated signalling resulting in a less immunogenic tumor microenvironment and that PBRM1 mutations correlate with lack of response to checkpoint inhibitor therapy in ccRCC patients.. |
| first_indexed | 2024-12-14T13:37:40Z |
| format | Article |
| id | doaj.art-2c2ffa7605cd4f008c5d3c780840e07f |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-14T13:37:40Z |
| publishDate | 2020-05-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-2c2ffa7605cd4f008c5d3c780840e07f2022-12-21T22:59:33ZengNature PortfolioNature Communications2041-17232020-05-0111111410.1038/s41467-020-15959-6PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinomaXian-De Liu0Wen Kong1Christine B. Peterson2Daniel J. McGrail3Anh Hoang4Xuesong Zhang5Truong Lam6Patrick G. Pilie7Haifeng Zhu8Kathryn E. Beckermann9Scott M. Haake10Sevinj Isgandrova11Margarita Martinez-Moczygemba12Nidhi Sahni13Nizar M. Tannir14Shiaw-Yih Lin15W. Kimryn Rathmell16Eric Jonasch17Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Biostatistics, The University of Texas MD Anderson Cancer CenterDepartment of Systems Biology, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Neuro-Oncology, The University of Texas MD Anderson Cancer CenterDivision of Hematology and Oncology, Vanderbilt University Medical CenterDivision of Hematology and Oncology, Vanderbilt University Medical CenterInstitute of Biosciences and Technology, Texas A&M Health Science CenterInstitute of Biosciences and Technology, Texas A&M Health Science CenterDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterDepartment of Systems Biology, The University of Texas MD Anderson Cancer CenterVanderbilt-Ingram Cancer Center, Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical CenterDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer CenterPBRM1, encoding for a subunit of the SWI/SNF complex, is the second most frequently mutated gene in clear cell renal cell carcinoma (ccRCC). Here, the authors show that PBRM1 loss reduces IFNγ-mediated signalling resulting in a less immunogenic tumor microenvironment and that PBRM1 mutations correlate with lack of response to checkpoint inhibitor therapy in ccRCC patients..https://doi.org/10.1038/s41467-020-15959-6 |
| spellingShingle | Xian-De Liu Wen Kong Christine B. Peterson Daniel J. McGrail Anh Hoang Xuesong Zhang Truong Lam Patrick G. Pilie Haifeng Zhu Kathryn E. Beckermann Scott M. Haake Sevinj Isgandrova Margarita Martinez-Moczygemba Nidhi Sahni Nizar M. Tannir Shiaw-Yih Lin W. Kimryn Rathmell Eric Jonasch PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma Nature Communications |
| title | PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma |
| title_full | PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma |
| title_fullStr | PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma |
| title_full_unstemmed | PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma |
| title_short | PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma |
| title_sort | pbrm1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma |
| url | https://doi.org/10.1038/s41467-020-15959-6 |
| work_keys_str_mv | AT xiandeliu pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT wenkong pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT christinebpeterson pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT danieljmcgrail pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT anhhoang pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT xuesongzhang pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT truonglam pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT patrickgpilie pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT haifengzhu pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT kathrynebeckermann pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT scottmhaake pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT sevinjisgandrova pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT margaritamartinezmoczygemba pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT nidhisahni pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT nizarmtannir pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT shiawyihlin pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT wkimrynrathmell pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma AT ericjonasch pbrm1lossdefinesanonimmunogenictumorphenotypeassociatedwithcheckpointinhibitorresistanceinrenalcarcinoma |